Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)
July 25, 2024 07:16 AM EDTUpdated 07:31 AM
R&D
Pharma

Roche cuts two more TIG­IT tri­als, plans ac­cel­er­at­ed time­line for obe­si­ty drugs

Amber Tong

A year in­to Roche’s com­pre­hen­sive port­fo­lio re­view, the Swiss phar­ma said it has now tak­en out 25% of new drug can­di­dates from its pipeline. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times